Alumis, Inc. (ALMS)
5.60
-0.53
(-8.65%)
USD |
NASDAQ |
Nov 13, 16:00
5.55
-0.05
(-0.89%)
After-Hours: 19:59
Alumis Shareholders Equity (Quarterly) : 378.42M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 378.42M |
| June 30, 2026 | 452.16M |
| March 31, 2026 | 567.02M |
| December 31, 2025 | 301.30M |
| September 30, 2025 | 384.77M |
| June 30, 2025 | 485.33M |
| Date | Value |
|---|---|
| March 31, 2025 | 168.31M |
| December 31, 2024 | 260.10M |
| September 30, 2024 | 348.39M |
| June 30, 2024 | 200.48M |
| March 31, 2024 | 109.65M |
| December 31, 2023 | 36.11M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Johnson & Johnson | 81.53B |
| BioAge Labs, Inc. | 346.45M |
| ANI Pharmaceuticals, Inc. | 637.11M |
| Corcept Therapeutics, Inc. | 833.74M |
| Veru, Inc. | 28.38M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 488.71M |
| Total Liabilities (Quarterly) | 110.29M |
| Debt to Equity Ratio | 0.0933 |
| Current Ratio | 5.574 |
| Net Debt Paydown Yield | 0.07% |